HRTX Q2 2019 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M+112.2% YoY

Gross Profit

$23M62.9% margin

Operating Income

-$52M-141.2% margin

Net Income

-$50M-137.0% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+16.0%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$25M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$412M

Total Liabilities

$106M

Stockholders' Equity

$305M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$17M	+112.2%
Gross Profit	$23M	$12M	+91.5%
Operating Income	-$52M	-$39M	-33.3%
Net Income	-$50M	-$39M	-29.9%